In a meta-analysis of blood pressure (BP) lowering trials, BP lowering resulted in a consistent proportional risk reduction in cardiovascular disease (CVD) down to a threshold of 120 mm Hg systolic BP (SBP). 1 This finding was reinforced by the Systolic Blood Pressure Intervention Trial (SPRINT) wherein BP lowering to an SBP target of <120 mm Hg relative to a target of <140 mm Hg reduced the risk of major cardiovascular events by a third among adults at high cardiovascular risk. 2 A corresponding trial in adults at intermediate cardiovascular risk also demonstrated that a 5 mm Hg reduction in BP was associated with a lower risk of major cardiovascular events in adults with a baseline BP >140 mm Hg. 3 If absolute risk of CVD is considered in the initiation of BP-lowering treatment, a proportion of United States (US) adults at elevated cardiovascular risk with BP below current guideline thresholds may warrant further BP lowering. However, the size and characteristics of this population are currently unknown. To inform public health efforts, we estimated the proportion and characteristics of US adults who may be eligible for treatment based on their absolute risk of CVD.
Brief CommuniCation
In a meta-analysis of blood pressure (BP) lowering trials, BP lowering resulted in a consistent proportional risk reduction in cardiovascular disease (CVD) down to a threshold of 120 mm Hg systolic BP (SBP). 1 This finding was reinforced by the Systolic Blood Pressure Intervention Trial (SPRINT) wherein BP lowering to an SBP target of <120 mm Hg relative to a target of <140 mm Hg reduced the risk of major cardiovascular events by a third among adults at high cardiovascular risk. 2 A corresponding trial in adults at intermediate cardiovascular risk also demonstrated that a 5 mm Hg reduction in BP was associated with a lower risk of major cardiovascular events in adults with a baseline BP >140 mm Hg. 3 If absolute risk of CVD is considered in the initiation of BP-lowering treatment, a proportion of United States (US) adults at elevated cardiovascular risk with BP below current guideline thresholds may warrant further BP lowering. However, the size and characteristics of this population are currently unknown. To inform public health efforts, we estimated the proportion and characteristics of US adults who may be eligible for treatment based on their absolute risk of CVD.
METHODS
The objective of our study was to estimate the number of adults that would warrant BP-lowering treatment if an absolute cardiovascular risk strategy was used to determine eligibility.
Study sample
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional survey on a representative sample of US residents, providing demographic and laboratory data on participants. This study used datasets from the NHANES 2005-2012 surveys, and applied previously described methods. 4 NHANES was approved by a research ethics committee and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from each participant.
Nonpregnant adults aged ≥50 years were included in this study. Age, race, and gender were self-reported. 
BACKGROUND
The Systolic Blood Pressure Intervention Trial (SPRINT) and the Heart Outcomes Prevention Evaluation 3 (HOPE-3) trial demonstrated the merits of blood pressure (BP) lowering to reduce cardiovascular events in intermediate to high cardiovascular risk adults. However, the population impact of an absolute risk-based strategy for BP lowering remains unclear.
METHODS
We examined 3 treatment thresholds using the National Health and Nutrition Examination Survey. First, the JNC8 guideline was used to determine treatment goals. Second, adults with a systolic BP (SBP) of 130 mm Hg and high cardiovascular risk (based on eligibility for SPRINT) were considered eligible for additional BP lowering. Finally, we combined the treatment threshold for high-risk adults with an SBP treatment threshold of 140 mm Hg for intermediate-risk adults that met the eligibility criteria for HOPE-3. NHANES guidelines 5 and in accordance with previous methods. 4 Participants with at least one BP measurement were included and up to 3 BP measurements were available per participant. Participants answering "yes" to the following questions were noted as being treated for hypertension: "Because of your high blood pressure/hypertension, have you ever been told to take prescribed medicine?" and "Are you currently taking medication to lower your blood pressure?" Selfreport was used to determine smoking history and identify participants with a family history of premature coronary artery disease (CAD) in any relative <50 years of age. Selfreport was also used to identify participants with a personal history of acute myocardial infarction (AMI), congestive heart failure, CAD, angina, or stroke. Diabetes was defined as self-reported diabetes or a HbA1c ≥6.5%. Dysglycemia, was defined in accordance with Heart Outcomes Prevention Evaluation 3 (HOPE-3) as prediabetes, impaired fasting glucose, impaired glucose tolerance, and diabetes that is controlled with diet only. Identification of adults with dysglycemia was based on self-report.
RESULTS

Under
We examined 3 treatment thresholds and each was examined sequentially and cumulatively. First, the JNC8 guideline 6 was used to determine treatment goals because we sought to demonstrate the extent to which it underestimates the participants that may be eligible for BP lowering. Participants were considered "At target" if they were treated with BP-lowering medication(s) and their BP was below target or if they were at target without BP-lowering medication. Participants were considered "Eligible for additional BP lowering" if their BP was at or above target. Second, adults with an SBP ≥130 mm Hg, were determined to be eligible for additional BP lowering if they were at high cardiovascular risk (≥15% based on the Framingham cardiovascular risk equation) or met the following inclusion criteria specified in SPRINT: age ≥75 years, presence of established CVD-AMI, congestive heart failure, CAD, or angina-or chronic kidney disease (CKD), defined as an estimated glomerular filtration rate 20-59 ml/min/1.73m 2 . 2 Third, we combined the second scenario with an intermediate-risk treatment strategy based on the HOPE-3 trial. 3 We examined an SBP treatment threshold of 140 mm Hg for adults who would be eligible for HOPE-3. Specifically, this included men and women who were ≥55 years and ≥60 years of age, respectively, who had at least one of the following characteristics as defined in HOPE-3: current or recent smoking history, low high-density lipoprotein cholesterol, dysglycemia, or a family history of premature CAD. 3 We were unable to apply the HOPE-3 inclusion criteria of waist-to-hip ratio because hip circumference was not measured in NHANES. Finally, we retained the treatment thresholds in the JNC8 guideline for high-risk adults excluded from SPRINT: age < 50 years, diabetes, ≥1 gram/day proteinuria, heart failure, stroke, and <20 ml/min/1.73m 2 estimated glomerular filtration rate. 2 We also retained the treatment thresholds in the JNC8 guideline for adults excluded from HOPE-3: age <55 years for men, age <60 years for women, established CVD (defined in our study as angina, CAD, AMI, stroke, congestive heart failure), serum creatinine >180 μmol/l, or estimated glomerular filtration rate <45 ml/min/1.73m2. 3 This was done to ensure that we were not generalizing the findings of SPRINT and HOPE-3 to large populations that were not studied.
Absolute 10-year cardiovascular risk was calculated using the Framingham general cardiovascular risk equation. 7 Adults with established CVD-AMI, stroke, or congestive heart failure-were considered high risk (≥15% predicted cardiovascular risk based on the Framingham risk equation). Using the 2011-2012 US population estimates provided by NHANES, we determined the corresponding number of US adults that would be eligible for BP lowering. We multiplied the total number of adults aged 50 years and older in 2011-2012 by the proportion that were nonpregnant, the proportion that had complete BP measurements and finally by any proportions corresponding to the groups of interest in our study (accounting for adults that could not be classified for our study due to missing data). Statistical analyses were conducted using Stata (version 14).
RESULTS
Between 2005 and 2012, NHANES included 9,204 adults who were ≥50 years of age and could be classified for this study. There were 8,662 (94%) adults with 3 BP measurements, 249 (3%) with 2 BP measurements, and 293 (3%) with 1 BP measurement. Under JNC8 guidelines, 77.9% of adults were at target while 22% were eligible for additional BP lowering. If a SBP treatment threshold of 130 mm Hg was used for individuals at high cardiovascular risk, 31.1% of adults (8.1 million additional adults) would be eligible for BP lowering (Table 1) . Furthermore, if a SBP treatment threshold of 140 mm Hg was used for intermediate-risk individuals based on the HOPE-3 eligibility criteria, the proportion eligible for BP lowering increased only slightly to 31.4% (8.3 million additional adults).
Based on the JNC8 guidelines, the proportion of patients eligible for BP lowering with prevalent AMI was 7.6%. With the risk-based treatment strategy, 6.7% of adults eligible for BP lowering had prevalent AMI under the high-risk strategy and 6.6% of adults had prevalent AMI under the intermediate strategy.
DISCUSSION
If cardiovascular risk is incorporated into current guidelines regarding BP-lowering treatment, 8.3 million US adults may warrant additional BP lowering. However, this increase was primarily among adults eligible for SPRINT as opposed to adults eligible for HOPE-3. The proportion of adults eligible for BP lowering with established CAD also decreased with the risk-based strategies, indicating that an absolute risk strategy would result in an increased emphasis on primary prevention.
There is no consensus on the extent to which the findings generated in SPRINT should be generalized. Some authors have supported a more conservative interpretation of SPRINT and do not advise intensive BP lowering for adults excluded from the trial. 8 In contrast, other authors support intensive BP lowering based on absolute risk. 9 In our study, we retained the or albumin-to-creatinine ratio ≥30 mg/g.
JNC8 guideline treatment thresholds for adults that were excluded from SPRINT because this approach would generate a conservative estimate of the number of adults needing additional BP lowering. If the results of SPRINT are applied more broadly, the number of adults that may be eligible for additional BP lowering would increase. The interpretation of the SPRINT trial in the forthcoming clinical guidelines from the American College of Cardiology and the American Heart Association will therefore have immense public health impact. It is also important to recognize that other interventions, beyond that of intensive BP lowering with medications may also serve to decrease the number of adults who are not at target. For instance, in a previous study of a system level changes in hypertension management-which included the creation of a hypertension registry, regular review of hypertension control across primary care settings, and provider feedbackinvestigators demonstrated marked improvement in hypertension control compared to national rates. 10 Implementation of system level changes in hypertension management may therefore reduce the need for additional BP-lowering medication as estimated in our study. Other efforts targeted at reducing socioeconomic and racial disparities in the initiation and treatment of elevated BP may also reduce the number of individuals who are not at target. 11 Finally, a robust cost-effectiveness analysis of intensive BP lowering has yet to be conducted. Further research, including the prespecified cost-effectiveness analysis of the SPRINT trial, are required to better inform public health resource allocation.
There are important limitations to this study. First, some participants only had a single BP measurement available. Second, diabetes was partially based on self-report, which may underestimate its actual prevalence. Third, BP measurements in SPRINT were taken in an office setting by a fully automated device after patients had been seated quietly without an observer present. This technique is at variance with the measurement techniques that were used in other trails and NHANES. Accordingly, the treatment targets of BP lowering achieved in SPRINT may need to be corrected by 5-10 mm Hg (equivalent to 125-130 mm Hg) if BP measurements are taken with an attendant present. 12 Fourth, we were unable to apply the waist-to-hip ratio eligibility criteria in HOPE-3. This would have led to an underestimate of the number of adults eligible for additional BP lowering.
Taken together, a large proportion of US adults may be eligible from more intensive BP lowering. This is largely due to adults who meet the eligibility criteria for the SPRINT study.
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